OR for arm fat mass = 1.13, 95% CI 1.001.27, P-value = 0.04), and 18:2 LA marginally associated with invasive MOC (OR = 1.23, 95% CI 1.011.50, P-value = 0.04)
Despite extensive research, disease-modifying treatments remain elusive, with current management primarily focusing on symptom control
Cuando se oxida, el glutatin queda inactivo y no puede cumplir su funcin como antioxidante
doi: 10.1016/j.rasd.2018.09.003
Gastrointestinal side effects are by far the most prevalent during early treatment: Nausea Very common (may affect more than 1 in 10 people), typically peaking during the first week and often improving over two to four weeks [1] [2] Vomiting Common (may affect up to 1 in 10 people), usually occurring alongside nausea [1] [2] Diarrhoea Common, may persist for several weeks Constipation Common, sometimes alternating with diarrhoea Abdominal pain or discomfort Common, ranging from mild cramping to more pronounced discomfort Dyspepsia (indigestion) Common Eructation (belching) Common Reduced appetite A therapeutic effect that may feel uncomfortable initially, affecting eating patterns These symptoms arise because semaglutide mimics the natural GLP-1 hormone, which slows gastric emptying and increases satiety
